Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.
This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.
https://www.statnews.com/2024/05/14/wegovy-alcohol-related-liver-disease-novo-nordisk/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.